EP4401727A1 — A stable ready to dilute injectable pharmaceutical formulation of mitomycin
Assigned to Intas Pharmaceuticals Ltd · Expires 2024-07-24 · 2y expired
What this patent protects
The present invention relates to a stable ready to dilute (RTD) injectable pharmaceutical formulation of Mitomycin or a pharmaceutically acceptable salt thereof. The said formulation further comprises N, N - Dimethylacetamide (DMAC), Polyethylene glycol (PEG) and optionally other…
USPTO Abstract
The present invention relates to a stable ready to dilute (RTD) injectable pharmaceutical formulation of Mitomycin or a pharmaceutically acceptable salt thereof. The said formulation further comprises N, N - Dimethylacetamide (DMAC), Polyethylene glycol (PEG) and optionally other pharmaceutically acceptable excipients. Further, the present invention discloses process for the preparation of the said formulation.
Drugs covered by this patent
- Mobic (MELOXICAM) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.